DUBLIN, Jan. 2, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will webcast its presentation at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, 2013. The webcast is scheduled to begin at 10:00 a.m. PST (6:00 p.m. GMT). Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals, will present an overview of the company and provide a business and financial update.
The webcast can be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. An archived version of the webcast will be available at the same location for at least one week following the presentation.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Luvox CR® (fluvoxamine maleate), FazaClo® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma. For further information, see www.jazzpharmaceuticals.com.
SOURCE Jazz Pharmaceuticals plc
William Craumer, Director, Investor Relations, Jazz Pharmaceuticals, Ireland, + 353 1 634 3211, or U.S., + 1 650 496 2750